申请人:Celltech R&D Limtied
公开号:US20040180914A1
公开(公告)日:2004-09-16
Pyrimidines of formula (1) are described
1
wherein Ar is an optionally substituted aromatic or heteroaromatic group;
R
1
is a hydrogen atom or a straight or branched chain alkyl group;
R
2
is a —X
1
—R
3
group where X
1
is a direct bond or a linker atom or group, and
R
3
is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.
描述了化学式(1)的嘧啶类化合物,其中Ar是可选取代的芳香族或杂环芳香族基团;R1是氢原子或直链或支链烷基;R2是—X1—R3基团,其中X1是直接键或连接原子或基团,R3是可选取代的脂肪族、环状脂肪族、杂原子脂肪族、杂环脂肪族、芳香族或杂环芳香族基团;以及其盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性KDR激酶和/或FGFr激酶抑制剂,可用于预防和治疗与血管生成相关的疾病状态。